APA (7th ed.) Citation

C, X., KK, H., JH, L., JS, C., T, S., NM, F., . . . P, T. (2023). Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut, 72(9), 1651. https://doi.org/10.1136/gutjnl-2022-328332

Chicago Style (17th ed.) Citation

C, Xu, et al. "Comprehensive Molecular Phenotyping of ARID1A-deficient Gastric Cancer Reveals Pervasive Epigenomic Reprogramming and Therapeutic Opportunities." Gut 72, no. 9 (2023): 1651. https://doi.org/10.1136/gutjnl-2022-328332.

MLA (9th ed.) Citation

C, Xu, et al. "Comprehensive Molecular Phenotyping of ARID1A-deficient Gastric Cancer Reveals Pervasive Epigenomic Reprogramming and Therapeutic Opportunities." Gut, vol. 72, no. 9, 2023, p. 1651, https://doi.org/10.1136/gutjnl-2022-328332.